EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The JAK1 /2 Inhibitor Baricitinib Ameliorates Neuroinflammation and Symptoms in an Animal Model of Essential Tremor

Mehran Ilaghi iD, Fatemeh Shahsavari iD, Monavareh Soti iD, Sina Elyasifar iD, Leila Bagherzadeh iD, Zeynab Pirmoradi iD, Mohammad Shabani iD

Pharmacology Research & Perspectives · 2026-08 · 14 (4)

DOI: 10.1002/prp2.70299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 10.07.2026. Verfasst von Mehran Ilaghi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. Hauptthemen laut MEDLINE: Purines, Pyrazoles, Azetidines, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kerman University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Essential tremor (ET) is one of the most prevalent adult‐onset movement disorders, which significantly impairs quality of life. So far, there are few therapeutic options with limited efficacy. This study investigated the therapeutic potential of baricitinib, a selective JAK1/2 inhibitor, in the harmaline‐induced model of ET. Male Swiss mice were randomly assigned to five groups ( n = 8): control, harmaline, and harmaline plus baricitinib at 10, 20, or 50 mg/kg doses. ET was induced using harmaline (10 mg/kg, i.p.). Baricitinib was administered orally daily for 14 days. Assessments included behavioral tests and cerebellar gene expression analysis of inflammatory markers (TNF‐α, IL‐6, NF‐κB), neurotrophic factors (BDNF), ET‐related targets (Lingo‐1, NMDA receptor), and histopathological evaluation. Baricitinib reduced harmaline‐induced tremor severity. The drug also significantly ameliorated anxiety‐like behaviors in elevated plus maze and open field tests, while reducing depressive‐like behavior in the tail suspension test. Passive avoidance outcomes changed in a direction suggestive of improved retention; however, the high‐dose findings should be interpreted cautiously because 50 mg/kg was associated with motor coordination impairment. Molecular analyses revealed baricitinib completely normalized cerebellar pro‐inflammatory cytokines TNF‐α and IL‐6 and suppressed NF‐κB expression. The drug restored BDNF levels and reduced Lingo‐1 expression. Histopathological examination also suggested reduced Purkinje cell degeneration, with 20 and 50 mg/kg doses reducing Purkinje cell degeneration to control levels. Baricitinib reduced tremor and affective behaviors in a harmaline‐induced ET model, though gait abnormalities persisted. Cognitive benefits at lower doses were observed, with cautious interpretation required for the high dose due to motor effects. Molecular and histological analyses supported anti‐inflammatory and neuroprotective effects, indicating selective benefits via neuroinflammatory modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesPyrazolesAzetidinesSulfonamidesNeuroinflammatory DiseasesAnimalsMaleDisease Models, AnimalMiceJanus Kinase 1HarmalineJanus Kinase 2Behavior, Animal

Stichwörter der Autor:innen

JAK inhibitorbaricitinibcerebellumessential tremorharmalineneuroinflammation

Substanzen

PurinesPyrazolesAzetidinesbaricitinibSulfonamidesJanus Kinase 1HarmalineJanus Kinase 2

Autor:innen und Institutionen

  • Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
  • Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Neuroscience Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.

ORCID-Profile: Mehran Ilaghi, Fatemeh Shahsavari, Monavareh Soti, Sina Elyasifar, Leila Bagherzadeh, Zeynab Pirmoradi, Mohammad Shabani

Förderung

  • Kerman University of Medical Sciences

Zitieren

APA

Ilaghi, M., Shahsavari, F., Soti, M., Elyasifar, S., Bagherzadeh, L., Pirmoradi, Z., & Shabani, M. (2026). The JAK1 /2 Inhibitor Baricitinib Ameliorates Neuroinflammation and Symptoms in an Animal Model of Essential Tremor. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70299

Vancouver

Ilaghi M, Shahsavari F, Soti M, Elyasifar S, Bagherzadeh L, Pirmoradi Z, et al. The JAK1 /2 Inhibitor Baricitinib Ameliorates Neuroinflammation and Symptoms in an Animal Model of Essential Tremor. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70299

BibTeX
@article{Ilaghi2026,
  author = {Ilaghi, Mehran and Shahsavari, Fatemeh and Soti, Monavareh and Elyasifar, Sina and Bagherzadeh, Leila and Pirmoradi, Zeynab and Shabani, Mohammad},
  title = {The JAK1 /2 Inhibitor Baricitinib Ameliorates Neuroinflammation and Symptoms in an Animal Model of Essential Tremor},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/prp2.70299}
}
Kostenlos starten →